Annual Net Income
-$257.83 M
-$65.55 M-34.09%
31 December 2023
Summary:
Sangamo Therapeutics annual net profit is currently -$257.83 million, with the most recent change of -$65.55 million (-34.09%) on 31 December 2023. During the last 3 years, it has fallen by -$136.84 million (-113.09%). SGMO annual net income is now -83611.36% below its all-time high of -$308.00 thousand, reached on 31 December 1996.SGMO Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$10.67 M
+$46.80 M+129.54%
30 September 2024
Summary:
Sangamo Therapeutics quarterly net profit is currently $10.67 million, with the most recent change of +$46.80 million (+129.54%) on 30 September 2024. Over the past year, it has increased by +$114.83 million (+110.25%). SGMO quarterly net income is now -49.50% below its all-time high of $21.13 million, reached on 31 March 2023.SGMO Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$134.84 M
+$114.83 M+45.99%
30 September 2024
Summary:
Sangamo Therapeutics TTM net profit is currently -$134.84 million, with the most recent change of +$114.83 million (+45.99%) on 30 September 2024. Over the past year, it has increased by +$114.67 million (+45.96%). SGMO TTM net income is now -4861.00% below its all-time high of -$2.72 million, reached on 31 March 2000.SGMO TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -34.1% | +110.3% | +46.0% |
| 3 y3 years | -113.1% | +122.4% | +25.7% |
| 5 y5 years | -277.3% | +139.1% | -13.9% |
SGMO Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -113.1% | at low | -49.5% | +109.3% | -6.0% | +58.9% |
| 5 y | 5 years | -277.3% | at low | -49.5% | +109.3% | -77.8% | +58.9% |
| alltime | all time | <-9999.0% | at low | -49.5% | +109.3% | -4861.0% | +58.9% |
Sangamo Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.67 M(-129.5%) | -$134.84 M(-46.0%) |
| June 2024 | - | -$36.13 M(-26.4%) | -$249.68 M(-23.9%) |
| Mar 2024 | - | -$49.09 M(-18.6%) | -$328.05 M(+27.2%) |
| Dec 2023 | -$257.83 M(+34.1%) | -$60.30 M(-42.1%) | -$257.83 M(+3.3%) |
| Sept 2023 | - | -$104.16 M(-9.0%) | -$249.51 M(+25.7%) |
| June 2023 | - | -$114.51 M(-641.8%) | -$198.50 M(+56.1%) |
| Mar 2023 | - | $21.13 M(-140.7%) | -$127.17 M(-33.9%) |
| Dec 2022 | -$192.28 M(+7.8%) | -$51.97 M(-2.2%) | -$192.28 M(+8.1%) |
| Sept 2022 | - | -$53.16 M(+23.1%) | -$177.80 M(+3.2%) |
| June 2022 | - | -$43.17 M(-1.8%) | -$172.33 M(-2.3%) |
| Mar 2022 | - | -$43.98 M(+17.3%) | -$176.33 M(-1.1%) |
| Dec 2021 | -$178.29 M(+47.3%) | -$37.50 M(-21.4%) | -$178.29 M(-1.7%) |
| Sept 2021 | - | -$47.69 M(+1.1%) | -$181.39 M(+34.1%) |
| June 2021 | - | -$47.17 M(+2.7%) | -$135.26 M(+9.1%) |
| Mar 2021 | - | -$45.93 M(+13.1%) | -$124.02 M(+2.5%) |
| Dec 2020 | -$121.00 M(+27.1%) | -$40.60 M(+2519.6%) | -$121.00 M(+59.5%) |
| Sept 2020 | - | -$1.55 M(-95.7%) | -$75.84 M(-25.4%) |
| June 2020 | - | -$35.93 M(-16.3%) | -$101.59 M(+5.9%) |
| Mar 2020 | - | -$42.91 M(-1042.1%) | -$95.95 M(+0.8%) |
| Dec 2019 | -$95.19 M(+39.3%) | $4.55 M(-116.7%) | -$95.19 M(-19.6%) |
| Sept 2019 | - | -$27.31 M(-9.8%) | -$118.41 M(+13.9%) |
| June 2019 | - | -$30.28 M(-28.2%) | -$103.94 M(+15.1%) |
| Mar 2019 | - | -$42.15 M(+125.8%) | -$90.30 M(+32.1%) |
| Dec 2018 | -$68.33 M(+25.2%) | -$18.66 M(+45.3%) | -$68.33 M(+8.9%) |
| Sept 2018 | - | -$12.84 M(-22.8%) | -$62.76 M(+0.8%) |
| June 2018 | - | -$16.64 M(-17.6%) | -$62.27 M(+7.1%) |
| Mar 2018 | - | -$20.19 M(+54.2%) | -$58.12 M(+6.5%) |
| Dec 2017 | -$54.57 M(-23.8%) | -$13.09 M(+6.0%) | -$54.57 M(+6.8%) |
| Sept 2017 | - | -$12.35 M(-1.1%) | -$51.10 M(-11.5%) |
| June 2017 | - | -$12.49 M(-24.9%) | -$57.71 M(-19.6%) |
| Mar 2017 | - | -$16.63 M(+72.8%) | -$71.80 M(+0.2%) |
| Dec 2016 | -$71.66 M(+76.1%) | -$9.62 M(-49.3%) | -$71.66 M(-5.8%) |
| Sept 2016 | - | -$18.96 M(-28.6%) | -$76.05 M(+14.7%) |
| June 2016 | - | -$26.57 M(+61.1%) | -$66.33 M(+27.9%) |
| Mar 2016 | - | -$16.49 M(+17.7%) | -$51.88 M(+27.5%) |
| Dec 2015 | -$40.70 M(+54.1%) | -$14.01 M(+51.6%) | -$40.70 M(+31.3%) |
| Sept 2015 | - | -$9.24 M(-23.8%) | -$31.01 M(+5.8%) |
| June 2015 | - | -$12.13 M(+128.0%) | -$29.31 M(+21.3%) |
| Mar 2015 | - | -$5.32 M(+23.2%) | -$24.16 M(-8.5%) |
| Dec 2014 | -$26.42 M(-0.8%) | -$4.32 M(-42.8%) | -$26.42 M(-12.6%) |
| Sept 2014 | - | -$7.54 M(+8.1%) | -$30.24 M(+4.9%) |
| June 2014 | - | -$6.98 M(-7.8%) | -$28.84 M(+5.6%) |
| Mar 2014 | - | -$7.57 M(-7.0%) | -$27.31 M(+2.6%) |
| Dec 2013 | -$26.62 M(+19.6%) | -$8.14 M(+32.5%) | -$26.62 M(+21.2%) |
| Sept 2013 | - | -$6.14 M(+12.8%) | -$21.96 M(+1.6%) |
| June 2013 | - | -$5.45 M(-20.8%) | -$21.60 M(-1.3%) |
| Mar 2013 | - | -$6.88 M(+98.0%) | -$21.88 M(-1.7%) |
| Dec 2012 | -$22.26 M(-37.7%) | -$3.48 M(-39.9%) | -$22.26 M(-11.5%) |
| Sept 2012 | - | -$5.79 M(+1.1%) | -$25.14 M(-13.0%) |
| June 2012 | - | -$5.73 M(-21.2%) | -$28.91 M(-13.5%) |
| Mar 2012 | - | -$7.27 M(+14.3%) | -$33.44 M(-6.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$35.75 M(+43.8%) | -$6.36 M(-33.4%) | -$35.75 M(-5.2%) |
| Sept 2011 | - | -$9.55 M(-6.9%) | -$37.71 M(+2.3%) |
| June 2011 | - | -$10.26 M(+7.1%) | -$36.85 M(+21.0%) |
| Mar 2011 | - | -$9.58 M(+15.1%) | -$30.45 M(+22.5%) |
| Dec 2010 | -$24.85 M(+33.7%) | -$8.32 M(-4.3%) | -$24.85 M(+31.3%) |
| Sept 2010 | - | -$8.70 M(+125.3%) | -$18.93 M(+25.5%) |
| June 2010 | - | -$3.86 M(-3.0%) | -$15.08 M(-4.1%) |
| Mar 2010 | - | -$3.98 M(+66.2%) | -$15.73 M(-15.4%) |
| Dec 2009 | -$18.59 M(-23.5%) | -$2.39 M(-50.7%) | -$18.59 M(-1.0%) |
| Sept 2009 | - | -$4.85 M(+7.5%) | -$18.77 M(-7.4%) |
| June 2009 | - | -$4.51 M(-34.0%) | -$20.26 M(-12.6%) |
| Mar 2009 | - | -$6.83 M(+165.4%) | -$23.16 M(-4.7%) |
| Dec 2008 | -$24.30 M(+13.1%) | -$2.57 M(-59.4%) | -$24.30 M(-14.4%) |
| Sept 2008 | - | -$6.34 M(-14.5%) | -$28.40 M(+7.9%) |
| June 2008 | - | -$7.42 M(-6.9%) | -$26.33 M(+9.3%) |
| Mar 2008 | - | -$7.97 M(+19.5%) | -$24.09 M(+12.2%) |
| Dec 2007 | -$21.48 M(+20.2%) | -$6.67 M(+56.3%) | -$21.48 M(-9.6%) |
| Sept 2007 | - | -$4.27 M(-17.6%) | -$23.76 M(+6.4%) |
| June 2007 | - | -$5.18 M(-3.3%) | -$22.33 M(+9.1%) |
| Mar 2007 | - | -$5.36 M(-40.1%) | -$20.48 M(+14.6%) |
| Dec 2006 | -$17.86 M(+34.4%) | -$8.95 M(+214.5%) | -$17.86 M(+53.9%) |
| Sept 2006 | - | -$2.85 M(-14.5%) | -$11.61 M(-6.6%) |
| June 2006 | - | -$3.33 M(+21.2%) | -$12.43 M(-0.4%) |
| Mar 2006 | - | -$2.74 M(+1.9%) | -$12.48 M(-6.1%) |
| Dec 2005 | -$13.29 M(-3.8%) | -$2.69 M(-26.6%) | -$13.29 M(-2.6%) |
| Sept 2005 | - | -$3.67 M(+8.5%) | -$13.64 M(-6.2%) |
| June 2005 | - | -$3.38 M(-4.9%) | -$14.55 M(+0.8%) |
| Mar 2005 | - | -$3.55 M(+16.8%) | -$14.43 M(+4.4%) |
| Dec 2004 | -$13.82 M(+32.4%) | -$3.04 M(-33.4%) | -$13.82 M(+10.9%) |
| Sept 2004 | - | -$4.57 M(+40.1%) | -$12.46 M(+19.0%) |
| June 2004 | - | -$3.26 M(+10.9%) | -$10.47 M(-0.1%) |
| Mar 2004 | - | -$2.94 M(+75.1%) | -$10.48 M(+0.5%) |
| Dec 2003 | -$10.43 M(-64.9%) | -$1.68 M(-35.0%) | -$10.43 M(+10.3%) |
| Sept 2003 | - | -$2.58 M(-21.1%) | -$9.46 M(-66.0%) |
| June 2003 | - | -$3.27 M(+13.1%) | -$27.82 M(-1.3%) |
| Mar 2003 | - | -$2.90 M(+310.1%) | -$28.17 M(-5.3%) |
| Dec 2002 | -$29.76 M(+17.9%) | -$706.00 K(-96.6%) | -$29.76 M(-8.2%) |
| Sept 2002 | - | -$20.94 M(+476.7%) | -$32.42 M(+12.2%) |
| June 2002 | - | -$3.63 M(-19.1%) | -$28.89 M(+4.4%) |
| Mar 2002 | - | -$4.49 M(+33.3%) | -$27.67 M(+9.6%) |
| Dec 2001 | -$25.25 M(+178.5%) | -$3.37 M(-80.7%) | -$25.25 M(+2.3%) |
| Sept 2001 | - | -$17.41 M(+621.1%) | -$24.69 M(+171.3%) |
| June 2001 | - | -$2.41 M(+17.1%) | -$9.10 M(+8.2%) |
| Mar 2001 | - | -$2.06 M(-26.5%) | -$8.41 M(-7.2%) |
| Dec 2000 | -$9.07 M(+138.6%) | -$2.81 M(+54.3%) | -$9.07 M(+44.8%) |
| Sept 2000 | - | -$1.82 M(+5.4%) | -$6.26 M(+40.9%) |
| June 2000 | - | -$1.73 M(-36.5%) | -$4.44 M(+63.5%) |
| Mar 2000 | - | -$2.72 M | -$2.72 M |
| Dec 1999 | -$3.80 M(+15.7%) | - | - |
| Dec 1998 | -$3.29 M(+134.6%) | - | - |
| Dec 1997 | -$1.40 M(+354.5%) | - | - |
| Dec 1996 | -$308.00 K | - | - |
FAQ
- What is Sangamo Therapeutics annual net profit?
- What is the all time high annual net income for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual net income year-on-year change?
- What is Sangamo Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly net income year-on-year change?
- What is Sangamo Therapeutics TTM net profit?
- What is the all time high TTM net income for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM net income year-on-year change?
What is Sangamo Therapeutics annual net profit?
The current annual net income of SGMO is -$257.83 M
What is the all time high annual net income for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual net profit is -$308.00 K
What is Sangamo Therapeutics annual net income year-on-year change?
Over the past year, SGMO annual net profit has changed by -$65.55 M (-34.09%)
What is Sangamo Therapeutics quarterly net profit?
The current quarterly net income of SGMO is $10.67 M
What is the all time high quarterly net income for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly net profit is $21.13 M
What is Sangamo Therapeutics quarterly net income year-on-year change?
Over the past year, SGMO quarterly net profit has changed by +$114.83 M (+110.25%)
What is Sangamo Therapeutics TTM net profit?
The current TTM net income of SGMO is -$134.84 M
What is the all time high TTM net income for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM net profit is -$2.72 M
What is Sangamo Therapeutics TTM net income year-on-year change?
Over the past year, SGMO TTM net profit has changed by +$114.67 M (+45.96%)